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aims: Permanent polymer based drug eluting stents (PP-DES) are alleged to have more very late stent thrombosis events compared to newer 
biodegradable polymer based drug eluting stents (BD-DES). To test the premise of BD-DES could improve clinical outcomes, we pooled the data from 
all the available randomized control trials (RCT) comparing the clinical performance of both the stents.
methods and results: Pubmed, Embace and Google scholar databases were searched for RCT comparing safety and efficacy of BD-DES vs. 
PP-DES. A total of 19 RCT, with a total of 19,109 patients were included in the meta-analysis, with 10,117 patients in BD-DES vs 8,772 patients 
in PP-DES. The mean follow up period was 17 months. Pooled analysis showed non-significant favorability to BD-DES, comparing events of stent 
thrombosis (OR=0.87, p=0.45), target lesion revascularization (OR=0.91, p=0.2), and death (OR=0.95, p=0.51). Studies with long term follow 
up data beyond one year, showed significantly lower very late stent thrombosis events in BD-DES compared to PP-DES (OR=0.35, p=0.01, I2 for 
heterogeneity 0%).
Conclusions: BD-DES are superior to PP-DES in decreasing very late stent thrombosis events and are at least non-inferior comparing over all hard 
outcomes.
 
